Changes in serum zinc levels in hepatitis C patients before and after treatment with direct‐acting antiviral agents
Aim Zinc supplementation therapy has been shown to improve the prognosis of patients with hepatitis C virus (HCV) infection. However, little is known about the changes in serum zinc levels with treatment using direct‐acting antiviral agents (DAAs). This prospective study investigated the changes in...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2019-11, Vol.49 (11), p.1353-1356 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1356 |
|---|---|
| container_issue | 11 |
| container_start_page | 1353 |
| container_title | Hepatology research |
| container_volume | 49 |
| creator | Suda, Toshikuni Okawa, Osamu Shirahashi, Ryosaku Tokutomi, Naohiko Tamano, Masaya |
| description | Aim
Zinc supplementation therapy has been shown to improve the prognosis of patients with hepatitis C virus (HCV) infection. However, little is known about the changes in serum zinc levels with treatment using direct‐acting antiviral agents (DAAs). This prospective study investigated the changes in serum zinc levels before and after treatment with DAAs in hepatitis C patients.
Methods
Thirty‐one patients with chronic hepatitis C or HCV‐related compensated cirrhosis who were treated with DAAs (glecaprevir/pibrentasvir or elbasvir/grazoprevir) were included in the study. Serum zinc and serum albumin levels were measured before DAA treatment (Baseline), at the end of treatment (EOT), and at 12 weeks after EOT (Follow‐up 12). The changes over time in the serum zinc and serum albumin levels were investigated.
Results
The mean age of the patients was 68.5 ± 12.1 (range, 40–86) years, and 17 (55%) were women. Based on the Japanese Society of Clinical Nutrition diagnostic criteria, 6 patients had zinc deficiency ( |
| doi_str_mv | 10.1111/hepr.13409 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2259355220</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2322985504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3819-491bfd6e2b3206cf03df2b787aedf4050cbac8136b293cecbeb74100549bbeba3</originalsourceid><addsrcrecordid>eNp9kclKBDEURYMoDq0bP0ACbkQozVTTUhonaFBEwV1IUq-6IzW0SUrRlZ_gN_olpm114cJkkUtyODxyEdql5IjGdTyDuTuiXJByBW3SImcJ4eJ-NWZeZEnGRbaBtrx_IITmhIl1tMFp3EVBN9EwnqluCh7bDntwQ4tfbWdwA0_QfF1GuQo2WI_HeJGgCx5rqHsHWHUVVnUAh4MDFdr4hp9tmOHKOjDh4-1dmWC7aQSDfbJONVhNF4JttFarxsPO9zlCd2ent-OLZHJ1fjk-mSSGF7RMREl1XWXANGckMzXhVc10XuQKqlqQlBitTEF5plnJDRgNOheUkFSUOmbFR-hg6Z27_nEAH2RrvYGmUR30g5eMpSVPU8ZIRPf_oA_94Lo4nWScsbJIUyIidbikjOu9d1DLubOtci-SErkoQy7KkF9lRHjvWznoFqpf9Of3I0CXwLNt4OUflbw4vb5ZSj8BpnGXKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322985504</pqid></control><display><type>article</type><title>Changes in serum zinc levels in hepatitis C patients before and after treatment with direct‐acting antiviral agents</title><source>Wiley Journals</source><creator>Suda, Toshikuni ; Okawa, Osamu ; Shirahashi, Ryosaku ; Tokutomi, Naohiko ; Tamano, Masaya</creator><creatorcontrib>Suda, Toshikuni ; Okawa, Osamu ; Shirahashi, Ryosaku ; Tokutomi, Naohiko ; Tamano, Masaya</creatorcontrib><description>Aim
Zinc supplementation therapy has been shown to improve the prognosis of patients with hepatitis C virus (HCV) infection. However, little is known about the changes in serum zinc levels with treatment using direct‐acting antiviral agents (DAAs). This prospective study investigated the changes in serum zinc levels before and after treatment with DAAs in hepatitis C patients.
Methods
Thirty‐one patients with chronic hepatitis C or HCV‐related compensated cirrhosis who were treated with DAAs (glecaprevir/pibrentasvir or elbasvir/grazoprevir) were included in the study. Serum zinc and serum albumin levels were measured before DAA treatment (Baseline), at the end of treatment (EOT), and at 12 weeks after EOT (Follow‐up 12). The changes over time in the serum zinc and serum albumin levels were investigated.
Results
The mean age of the patients was 68.5 ± 12.1 (range, 40–86) years, and 17 (55%) were women. Based on the Japanese Society of Clinical Nutrition diagnostic criteria, 6 patients had zinc deficiency (<60 μg/dL), and 21 patients had subclinical zinc deficiency (60–80 μg/dL). Significant differences in serum zinc levels were seen between Baseline and EOT (P = 0.01) and between EOT and Follow‐up 12 (P = 0.0003). There was no significant difference in serum albumin levels between Baseline and EOT (P = 0.76), but a significant increase was seen between EOT and Follow‐up 12 (P = 0.01).
Conclusions
Increases in serum zinc are directly related to DAA treatment and are not a result of increases in albumin. Inhibition of the non‐structural protein (NS)3 and NS5A by DAAs could be associated with the improvement of serum zinc levels in hepatitis C patients.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13409</identifier><identifier>PMID: 31313881</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Albumin ; Antiviral agents ; Cirrhosis ; Dietary supplements ; direct‐acting antiviral agent ; Hepatitis ; Hepatitis C ; Interferon ; Liver cirrhosis ; Nutrient deficiency ; Nutrition therapy ; Patients ; serum zinc ; Zinc</subject><ispartof>Hepatology research, 2019-11, Vol.49 (11), p.1353-1356</ispartof><rights>2019 The Japan Society of Hepatology</rights><rights>2019 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3819-491bfd6e2b3206cf03df2b787aedf4050cbac8136b293cecbeb74100549bbeba3</citedby><cites>FETCH-LOGICAL-c3819-491bfd6e2b3206cf03df2b787aedf4050cbac8136b293cecbeb74100549bbeba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13409$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13409$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31313881$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suda, Toshikuni</creatorcontrib><creatorcontrib>Okawa, Osamu</creatorcontrib><creatorcontrib>Shirahashi, Ryosaku</creatorcontrib><creatorcontrib>Tokutomi, Naohiko</creatorcontrib><creatorcontrib>Tamano, Masaya</creatorcontrib><title>Changes in serum zinc levels in hepatitis C patients before and after treatment with direct‐acting antiviral agents</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim
Zinc supplementation therapy has been shown to improve the prognosis of patients with hepatitis C virus (HCV) infection. However, little is known about the changes in serum zinc levels with treatment using direct‐acting antiviral agents (DAAs). This prospective study investigated the changes in serum zinc levels before and after treatment with DAAs in hepatitis C patients.
Methods
Thirty‐one patients with chronic hepatitis C or HCV‐related compensated cirrhosis who were treated with DAAs (glecaprevir/pibrentasvir or elbasvir/grazoprevir) were included in the study. Serum zinc and serum albumin levels were measured before DAA treatment (Baseline), at the end of treatment (EOT), and at 12 weeks after EOT (Follow‐up 12). The changes over time in the serum zinc and serum albumin levels were investigated.
Results
The mean age of the patients was 68.5 ± 12.1 (range, 40–86) years, and 17 (55%) were women. Based on the Japanese Society of Clinical Nutrition diagnostic criteria, 6 patients had zinc deficiency (<60 μg/dL), and 21 patients had subclinical zinc deficiency (60–80 μg/dL). Significant differences in serum zinc levels were seen between Baseline and EOT (P = 0.01) and between EOT and Follow‐up 12 (P = 0.0003). There was no significant difference in serum albumin levels between Baseline and EOT (P = 0.76), but a significant increase was seen between EOT and Follow‐up 12 (P = 0.01).
Conclusions
Increases in serum zinc are directly related to DAA treatment and are not a result of increases in albumin. Inhibition of the non‐structural protein (NS)3 and NS5A by DAAs could be associated with the improvement of serum zinc levels in hepatitis C patients.</description><subject>Albumin</subject><subject>Antiviral agents</subject><subject>Cirrhosis</subject><subject>Dietary supplements</subject><subject>direct‐acting antiviral agent</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Interferon</subject><subject>Liver cirrhosis</subject><subject>Nutrient deficiency</subject><subject>Nutrition therapy</subject><subject>Patients</subject><subject>serum zinc</subject><subject>Zinc</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kclKBDEURYMoDq0bP0ACbkQozVTTUhonaFBEwV1IUq-6IzW0SUrRlZ_gN_olpm114cJkkUtyODxyEdql5IjGdTyDuTuiXJByBW3SImcJ4eJ-NWZeZEnGRbaBtrx_IITmhIl1tMFp3EVBN9EwnqluCh7bDntwQ4tfbWdwA0_QfF1GuQo2WI_HeJGgCx5rqHsHWHUVVnUAh4MDFdr4hp9tmOHKOjDh4-1dmWC7aQSDfbJONVhNF4JttFarxsPO9zlCd2ent-OLZHJ1fjk-mSSGF7RMREl1XWXANGckMzXhVc10XuQKqlqQlBitTEF5plnJDRgNOheUkFSUOmbFR-hg6Z27_nEAH2RrvYGmUR30g5eMpSVPU8ZIRPf_oA_94Lo4nWScsbJIUyIidbikjOu9d1DLubOtci-SErkoQy7KkF9lRHjvWznoFqpf9Of3I0CXwLNt4OUflbw4vb5ZSj8BpnGXKA</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Suda, Toshikuni</creator><creator>Okawa, Osamu</creator><creator>Shirahashi, Ryosaku</creator><creator>Tokutomi, Naohiko</creator><creator>Tamano, Masaya</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201911</creationdate><title>Changes in serum zinc levels in hepatitis C patients before and after treatment with direct‐acting antiviral agents</title><author>Suda, Toshikuni ; Okawa, Osamu ; Shirahashi, Ryosaku ; Tokutomi, Naohiko ; Tamano, Masaya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3819-491bfd6e2b3206cf03df2b787aedf4050cbac8136b293cecbeb74100549bbeba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Albumin</topic><topic>Antiviral agents</topic><topic>Cirrhosis</topic><topic>Dietary supplements</topic><topic>direct‐acting antiviral agent</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Interferon</topic><topic>Liver cirrhosis</topic><topic>Nutrient deficiency</topic><topic>Nutrition therapy</topic><topic>Patients</topic><topic>serum zinc</topic><topic>Zinc</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suda, Toshikuni</creatorcontrib><creatorcontrib>Okawa, Osamu</creatorcontrib><creatorcontrib>Shirahashi, Ryosaku</creatorcontrib><creatorcontrib>Tokutomi, Naohiko</creatorcontrib><creatorcontrib>Tamano, Masaya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suda, Toshikuni</au><au>Okawa, Osamu</au><au>Shirahashi, Ryosaku</au><au>Tokutomi, Naohiko</au><au>Tamano, Masaya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in serum zinc levels in hepatitis C patients before and after treatment with direct‐acting antiviral agents</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2019-11</date><risdate>2019</risdate><volume>49</volume><issue>11</issue><spage>1353</spage><epage>1356</epage><pages>1353-1356</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
Zinc supplementation therapy has been shown to improve the prognosis of patients with hepatitis C virus (HCV) infection. However, little is known about the changes in serum zinc levels with treatment using direct‐acting antiviral agents (DAAs). This prospective study investigated the changes in serum zinc levels before and after treatment with DAAs in hepatitis C patients.
Methods
Thirty‐one patients with chronic hepatitis C or HCV‐related compensated cirrhosis who were treated with DAAs (glecaprevir/pibrentasvir or elbasvir/grazoprevir) were included in the study. Serum zinc and serum albumin levels were measured before DAA treatment (Baseline), at the end of treatment (EOT), and at 12 weeks after EOT (Follow‐up 12). The changes over time in the serum zinc and serum albumin levels were investigated.
Results
The mean age of the patients was 68.5 ± 12.1 (range, 40–86) years, and 17 (55%) were women. Based on the Japanese Society of Clinical Nutrition diagnostic criteria, 6 patients had zinc deficiency (<60 μg/dL), and 21 patients had subclinical zinc deficiency (60–80 μg/dL). Significant differences in serum zinc levels were seen between Baseline and EOT (P = 0.01) and between EOT and Follow‐up 12 (P = 0.0003). There was no significant difference in serum albumin levels between Baseline and EOT (P = 0.76), but a significant increase was seen between EOT and Follow‐up 12 (P = 0.01).
Conclusions
Increases in serum zinc are directly related to DAA treatment and are not a result of increases in albumin. Inhibition of the non‐structural protein (NS)3 and NS5A by DAAs could be associated with the improvement of serum zinc levels in hepatitis C patients.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31313881</pmid><doi>10.1111/hepr.13409</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2019-11, Vol.49 (11), p.1353-1356 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2259355220 |
| source | Wiley Journals |
| subjects | Albumin Antiviral agents Cirrhosis Dietary supplements direct‐acting antiviral agent Hepatitis Hepatitis C Interferon Liver cirrhosis Nutrient deficiency Nutrition therapy Patients serum zinc Zinc |
| title | Changes in serum zinc levels in hepatitis C patients before and after treatment with direct‐acting antiviral agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A49%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20serum%20zinc%20levels%20in%20hepatitis%20C%20patients%20before%20and%20after%20treatment%20with%20direct%E2%80%90acting%20antiviral%20agents&rft.jtitle=Hepatology%20research&rft.au=Suda,%20Toshikuni&rft.date=2019-11&rft.volume=49&rft.issue=11&rft.spage=1353&rft.epage=1356&rft.pages=1353-1356&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13409&rft_dat=%3Cproquest_cross%3E2322985504%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322985504&rft_id=info:pmid/31313881&rfr_iscdi=true |